Analysts have been eager to weigh in on the Healthcare sector with new ratings on Madrigal Pharmaceuticals (MDGL – Research Report) and Warby Parker (WRBY – Research Report).
Madrigal Pharmaceuticals (MDGL)
In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Hold rating on Madrigal Pharmaceuticals, with a price target of $200.00. The company’s shares closed last Thursday at $206.72.
According to TipRanks.com, Mamtani has 0 stars on 0-5 stars ranking scale with an average return of
Madrigal Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $367.93.
See today’s best-performing stocks on TipRanks >>
Warby Parker (WRBY)
In a report released today, Mark Mahaney from Evercore ISI reiterated a Buy rating on Warby Parker, with a price target of $19.00. The company’s shares closed last Thursday at $14.58.
According to TipRanks.com, Mahaney is a top 100 analyst with an average return of
Warby Parker has an analyst consensus of Strong Buy, with a price target consensus of $17.71, a 20.3% upside from current levels. In a report issued on May 2, Telsey Advisory also maintained a Buy rating on the stock with a $19.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MDGL:
- Madrigal price target lowered to $390 from $425 at H.C. Wainwright
- Madrigal Pharmaceuticals price target lowered to $381 from $397 at JMP Securities
- Madrigal Pharmaceuticals price target lowered to $382 from $389 at Citi
- Madrigal Pharmaceuticals’ Strategic Stock Sales Agreements
- Madrigal Pharmaceuticals management to meet with Oppenheimer
